Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Police say violent crime improving in downtown Raleigh, but more work is needed
Recommended
Back to school guide: Buses, lunches, key dates
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Karuna Therapeutics Inc
(NQ:
KRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Karuna Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect
February 27, 2024
Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks.
Via
Benzinga
Karuna Therapeutics: Q4 Earnings Insights
February 22, 2024
Via
Benzinga
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
February 22, 2024
From
Karuna Therapeutics, Inc.
Via
Business Wire
Mental Health Mavericks: 3 Stocks Changing the Game
February 21, 2024
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.
Via
InvestorPlace
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
February 16, 2024
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...
Via
Benzinga
Mizuho Downgrades Karuna Therapeutics: Here's What You Need To Know
January 26, 2024
Via
Benzinga
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
February 14, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
February 06, 2024
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
February 05, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
January 30, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
January 26, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
ABBV: This Top Biotech Just Went On A Buying Spree
January 25, 2024
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).
Via
Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
January 22, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bullish Continuation In '24? 3 Market Areas To Watch
January 10, 2024
This article discusses 3 market areas that should outperform dramatically over the next 12 months...
Via
Talk Markets
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
January 04, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
December 31, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
December 29, 2023
The major indexes boast big annual gains with the Dow at record highs.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
December 28, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
December 26, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst
December 26, 2023
H.C.
Via
Benzinga
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
December 26, 2023
Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.
Via
Investor's Business Daily
Why Is RayzeBio (RYZB) Stock Up 100% Today?
December 26, 2023
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024.
Via
InvestorPlace
Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
December 26, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 25, 2023
Via
Benzinga
Bristol-Myers Buying Karuna Signals A Biotech Boom Ahead: Jefferies
December 24, 2023
Bristol-Myers Squibb is buying Karuna Therapeutics for $14 billion. Karuna Therapeutics Inc stock jumped nearly 50% on Friday. Jefferies analyst Michael Yee shares his view on biotech stocks.
Via
Talk Markets
Dow Edges Lower; Nike Sales Miss Estimates
December 22, 2023
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&P 500 also...
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.